Relapse of leprosy after multidrug therapy

Journal of the Medical Association of Thailand

Volumn 79, Issue 10, 1996, Pages

  Dasananjali, Krongkarn ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; RIFAMPICIN;

ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; LEPROSY; MAJOR CLINICAL STUDY; MALE; RELAPSE; SKIN BIOPSY;

DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LEPROSTATIC AGENTS; LEPROSY; MALE; MYCOBACTERIUM LEPRAE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 0030447127     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. WHO Study Group. Chemotherapy of leprosy for control programmes. Technical Report Series 675. Geneva, World Health Organization, 1982, pp. 21-6.
2. Becx-Bleumink M. Relapses among leprosy patients treated with multidrug therapy: Experience in the leprosy control programme of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; Practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses. Int J Lepr 1992; 60: 421-35.
3. van Brakel W, Kist P, Noble S, O' Toole L. Relapses after multidrug therapy for leprosy : a preliminary report of 22 cases in West Nepal. Lepr Rev 1989; 60: 45-50.
4. Boerrigter G, Ponninghaus JM, Fine PEM, Wilson R J. Four year follow up results of a WHO recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr 1999; 59: 255-61.
5. Marchoux Chemotherapy Study Group. Relapses in multibacillary leprosy patients after stopping treatment with rifampin-containing combined regimens. Int J Lepr 1992; 60: 525-35.
6. WHO. Risk of relapse in leprosy. WHO/CTD/ LEP/94.1 Geneva, World Health Organization, 1994.
7. Grugni A, Nadkami NJ, Kini MS, Mehta VR. Relapses in paucibacillary leprosy after MDT-a clinical study. Int J Lepr 1990; 58: 19-24.
8. Reddy PK, Mohinuddin SK. Pattern of relapses in paucibacillary leprosy patients treated with MDT (WHO 1982) Indian J Lepr 1988; 60: 581-8.
9. Pattyn SR, Husser JA, Baquillon G, Maiga M, Jamet P. Evaluation of five treatment regimens using either dapsone monotherapy or several doses of rifampicin in the treatment of paucibacillary leprosy. Lepr Rev 1990; 61: 151-6.
10. WHO. Standard protocol for chemotherapy trials in non-lepromatous leprosy. TDR/THELEP/ PROTOCOL/82.1 Geneva, World Helath Organization, 1982.
11. WHO. Chemotherapy of leprosy. Technical Report Series 847. Geneva, World Helath Organization, 1994, pp. 4-12.
12. WHO. A guide to eliminating leprosy as a public health problem. WHO/LEP/ 95.1 Geneva, World Health Organization, 1995, pp. 20-2.
13. van Brakel WH, Soldenhoff R, McDougall AC. The allocation of leprosy patients into paucibacillary and multibacillary groups for multidrug therapy, taking into account the number of body areas affected by skin, or skin and nerves lesions. Lepr Rev 1992; 63: 231-46.